Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) announced that four of its top executives—including founder, Chairman and General Manager Dr. Wang Qinghua—have each executed a voluntary lock-up undertaking on their personally held shares.

The commitment: Dr. Wang, Executive Directors Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing have agreed not to dispose of any of their direct or indirect equity interests in Innogen Pharmaceutical for six months starting 15 August 2026. This date coincides with the expiry of the statutory lock-up for the Company’s controlling shareholder following its Main Board listing on the Hong Kong Stock Exchange (HKEX).

Stakeholder details: • Dr. Wang serves as founder, Chairman, Executive Director and General Manager and is a substantial shareholder of Innogen Pharmaceutical. • Ms. Jiang holds equity in Hong Kong Invengen Pharmaceutical Technology Co., Limited and is a limited partner of Guangzhou Nuopa Enterprise Management Partnership (Limited Partnership), the Company’s employee incentive platform. • Ms. Xu and Mr. Huang are Executive Directors and limited partners of Guangzhou Nuopa.

Rationale: According to the announcement, the extension reflects the executives’ “strong confidence in the Company’s future prospect and long-term development.”

Market implications: The self-imposed restriction delays any potential share sales by these insiders until at least 15 February 2027, effectively extending alignment between senior management and minority shareholders beyond the mandatory IPO lock-up.

Investors are advised by the Board to exercise caution when trading Innogen Pharmaceutical securities.